Virological features of chronic hepatitis B patients with metabolic associated fatty liver disease： A stratified analysis

Lingna LYU; Qi LI; Wenxia MA; Huiguo DING; Hui LIU

doi:10.12449/JCH240710

Volume 40 Issue 7

Jul. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(7): 1343-1348

PDF( 1033 KB)

Virological features of chronic hepatitis B patients with metabolic associated fatty liver disease： A stratified analysis

DOI: 10.12449/JCH240710

Lingna LYU^{a, b},
Qi LI^{a, b},
Wenxia MA^{a, b},
Huiguo DING^{a, b},
Hui LIU^{c
,
,
,}

a.
Department of Hepatology and Gastroenterology Capital Medical University, Beijing 100069, China
b.
Laboratory for Clinical Medicine Capital Medical University, Beijing 100069, China
c.
Department of Pathology Beijing YouAn Hospital Capital Medical University, Beijing 100069, China

Research funding:

National Natural Science Foundation of China (82372260);

Beijing Natural Science Foundation Haidian Original Innovation Joint Fund (L202023);

Beijing YouAn Hospital Construction of Talent Pool Program (YARCKB2023003)

More Information

Corresponding author: LIU Hui， liuhuier@ccmu.edu.cn （ORCID： 0000-0001-8212-5285）
Received Date: 2024-04-09
Accepted Date: 2024-05-28
Published Date: 2024-07-25

Abstract

Abstract

Objective To investigate the virological features of patients with chronic hepatitis B （CHB） and metabolic associated fatty liver disease （MAFLD） through a stratified analysis. Methods A retrospective analysis was performed for 131 patients with CHB and MAFLD and 168 patients with CHB alone who underwent percutaneous liver biopsy and did not receive antiviral therapy or withdrew from drugs for more than 6 months in Beijing YouAn Hospital， Capital Medical University， from January 1， 2013 to December 31， 2019. The two groups were compared in terms of general data， biochemical parameters， and virological parameters. The patients in the two groups were stratified according to liver inflammation grade （G） and liver fibrosis stage （S）， and the patients with CHB and MAFLD were further analyzed based on the degree of hepatic steatosis and NAFLD activity score （NAS）. Virological features （the serum levels of HBV DNA and HBV HBsAg） were compared between groups. The Wilcoxon test was used for comparison of continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between multiple groups and further comparison between two groups； the chi-square test was used for comparison of categorical data between two groups. Results Compared with the CHB group， the CHB+MAFLD group had a significantly higher proportion of male patients， a significantly higher proportion of patients with hypertension or type 2 diabetes mellitus， and significantly higher levels of the blood biochemical parameters of triglyceride， low-density lipoprotein cholesterol， apolipoprotein B， alanine aminotransferase， gamma-glutamyl transpeptidase， uric acid， and fasting blood glucose （all P<0.05）， as well as significantly lower levels of high-density lipoprotein cholesterol， apolipoprotein A1， and HBV DNA （all P<0.05）. The stratified analysis based on liver fibrosis stage showed that for both the patients with CHB alone and those with CHB and MAFLD， the significant fibrosis （S2‍ ‍—‍ ‍4） group had a significantly lower level of HBV DNA than the non-significant fibrosis （S0‍ ‍—‍ ‍1） group （P<0.05）， and for the patients with CHB alone， the significant fibrosis （S2‍ ‍—‍ ‍4） group had a significantly lower level of HBsAg than the non-significant fibrosis （S0‍ ‍—‍ ‍1） group （P<0.05）. The stratified analysis based on inflammation grade showed that for the patients with CHB and MAFLD， the high inflammation grade （G3） group had a significantly higher level of HBV DNA than the low inflammation grade （G1‍ ‍—‍ ‍2） group （P<0.05）， and in the low inflammation grade （G1‍ ‍—‍ ‍2） group， the patients with CHB and MAFLD had a significantly lower level of HBsAg than the patients with CHB alone （P<0.05）. The stratified analysis based on the degree of hepatic steatosis showed that the level of HBV DNA gradually decreased with the increase in the degree of steatosis， and the severe steatosis group had a significantly lower level of HBV DNA than the mild group （P<0.05）， while there was no significant difference in HBsAg level between the groups with different degrees of hepatic steatosis （P>0.05）. The stratified analysis based on NAS score showed that the NAS≥4 group had significantly higher levels of HBV DNA and HBsAg than the NAS<4 group （both P<0.05）. Conclusion Patients with CHB and MAFLD have significant abnormalities in metabolic markers and aminotransferases， while virological indicators show different features in stratified analyses based on various indicators.
- Hepatitis B， Chronic,
- Metabolic Associated Fatty Liver Disease,
- Virology

FullText(HTML)

References(21)

References

[1]	JENG WJ, PAPATHEODORIDIS GV, LOK ASF. Hepatitis B[J]. Lancet, 2023, 401( 10381): 1039- 1052. DOI: 10.1016/S0140-6736(22)01468-4.
[2]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
[3]	JIANG DX, CHEN C, LIU XX, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: A systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9( 23): 1718. DOI: 10.21037/atm-21-3052.
[4]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Infect Dis Inf, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
[5]	HUANG SC, LIU CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives[J]. Clin Mol Hepatol, 2023, 29( 2): 320- 331. DOI: 10.3350/cmh.2022.0422.
[6]	HUANG SC, SU TH, TSENG TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B[J]. Hepatol Int, 2023, 17( 5): 1139- 1149. DOI: 10.1007/s12072-023-10545-6.
[7]	WANG CC, KAO JH. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study[J]. Hepatology, 2017, 66( 2): 681. DOI: 10.1002/hep.29252.
[8]	PAIS R, RUSU E, ZILISTEANU D, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease[J]. Eur J Intern Med, 2015, 26( 1): 30- 36. DOI: 10.1016/j.ejim.2014.12.001.
[9]	HUANG JF, JING ML, WANG CY, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study[J]. J Med Virol, 2020, 92( 8): 1191- 1197. DOI: 10.1002/jmv.25621.
[10]	LIU WH, LIU H, DING HG, et al. Clinical characteristics and prognosis of patients with chronic hepatitis B combined with metabolic associated fatty liver disease[J]. J Clin Hepatol, 2022, 38( 10): 2230- 2235. DOI: 10.3969/j.issn.1001-5256.2022.10.007. 刘伟鸿, 刘晖, 丁惠国, 等. 慢性乙型肝炎合并代谢相关性脂肪性肝病的临床特征及预后影响因素分析[J]. 临床肝胆病杂志, 2022, 38( 10): 2230- 2235. DOI: 10.3969/j.issn.1001-5256.2022.10.007.
[11]	van KLEEF LA, CHOI HSJ, BROUWER WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3( 5): 100350. DOI: 10.1016/j.jhepr.2021.100350.
[12]	HAAM JH, LEE YK, SUH E, et al. Characteristics of urine organic acid metabolites in nonalcoholic fatty liver disease assessed using magnetic resonance imaging with elastography in Korean adults[J]. Diagnostics(Basel), 2022, 12( 5): 1199. DOI: 10.3390/diagnostics12051199.
[13]	ZHAO CC, WANG AP, LI LX, et al. Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes[J]. J Diabetes Complications, 2016, 30( 6): 1074- 1080. DOI: 10.1016/j.jdiacomp.2016.04.017.
[14]	WANG RS, XUE FB, WANG LP, et al. Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States[J]. J Clin Lab Anal, 2022, 36( 8): e24590. DOI: 10.1002/jcla.24590.
[15]	HUI RWH, SETO WK, CHEUNG KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study[J]. J Viral Hepat, 2018, 25( 1): 97- 104. DOI: 10.1111/jvh.12766.
[16]	WANG MM, WANG GS, SHEN F, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dis Sci, 2014, 59( 10): 2571- 2579. DOI: 10.1007/s10620-014-3180-9.
[17]	ZHENG Q, ZOU BY, WU YK, et al. Systematic review with meta-analysis: Prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54( 9): 1100- 1109. DOI: 10.1111/apt.16595.
[18]	YI ST, REN GH, ZHU Y, et al. Correlation analysis of hepatic steatosis and hepatitis B virus: A cross-sectional study[J]. Virol J, 2024, 21( 1): 22. DOI: 10.1186/s12985-023-02277-8.
[19]	LIU QC, MU MY, CHEN H, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress[J]. Mol Cell Biochem, 2022, 477( 11): 2481- 2491. DOI: 10.1007/s11010-021-04143-z.
[20]	YOON S, JUNG J, KIM T, et al. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ, controls hepatitis B virus replication[J]. Virology, 2011, 409( 2): 290- 298. DOI: 10.1016/j.virol.2010.10.024.
[21]	YANG T, LI J. Chronic hepatitis B comorbid with nonalcoholic fatty liver disease: Contemporary insights and controversies[J]. J Clin Hepatol, 2023, 39( 8): 1797- 1804. DOI: 10.3969/j.issn.1001-5256.2023.08.005. 阳韬, 李军. 慢性乙型肝炎合并非酒精性脂肪性肝病: 当前的认识与争议[J]. 临床肝胆病杂志, 2023, 39( 8): 1797- 1804. DOI: 10.3969/j.issn.1001-5256.2023.08.005.

Relative Articles

[1]	Linna YUAN, Yihui CHEN, Hengbin NA, Jie LU, Ye LIU, Wu LI. Primary biliary cholangitis with metabolic associated fatty liver disease： Clinical features and risk factors[J]. Journal of Clinical Hepatology, 2024, 40(8): 1598-1604. doi: 10.12449/JCH240815
[2]	Yingdie ZHU, Zhijiao ZHANG, Guilin ZHANG, Yunkun GAO, Mengyao ZHENG, Hua HUANG, Gongfang ZHAO. Association of metabolic associated fatty liver disease with carotid atherosclerotic plaque and stenosis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1591-1597. doi: 10.12449/JCH240814
[3]	Nan GENG, Wenjing NI, Fajuan RUI, Jie LI. Chronic hepatitis B virus infection and metabolic associated fatty liver disease： The known and unknown aspects[J]. Journal of Clinical Hepatology, 2024, 40(3): 441-445. doi: 10.12449/JCH240301
[4]	Hui ZHUANG. Further discussion on the antiviral treatment of chronic hepatitis B patients with indeterminate phase[J]. Journal of Clinical Hepatology, 2023, 39(10): 2273-2276. doi: 10.3969/j.issn.1001-5256.2023.10.001
[5]	Zhaobin CHEN, Liyuan HUANG, Bingyuan WANG, Junping SHI, Jing ZHANG. Research advances in the association between metabolic associated fatty liver and type 2 diabetes mellitus and the mechanism of comorbidity[J]. Journal of Clinical Hepatology, 2023, 39(10): 2454-2459. doi: 10.3969/j.issn.1001-5256.2023.10.025
[6]	Tao JIANG, Wenxian OUYANG, Yanfang TAN, Zhen KANG, Shuangjie LI. Changes in the frequency, phenotype, and function of mucosal-associated invariant T lymphocytes in peripheral blood of children with metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(3): 562-566. doi: 10.3969/j.issn.1001-5256.2023.03.012
[7]	Xiaodong ZHOU, Na TIAN, Minghua ZHENG. Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2336-2339. doi: 10.3969/j.issn.1001-5256.2023.10.010
[8]	Shuang ZHANG, Xiaohui LIU, Gang WANG, Li ZHANG, Yunjie ZHU, Jian WU, Yali LIU, Jing ZHANG. Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population[J]. Journal of Clinical Hepatology, 2022, 38(3): 547-552. doi: 10.3969/j.issn.1001-5256.2022.03.011
[9]	Ling LUO, Xianhua LIAO, Bihui ZHONG. Research advances in vitamin D deficiency and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(7): 1641-1645. doi: 10.3969/j.issn.1001-5256.2022.07.034
[10]	Yunxia WU, Chengliang LI, Xiaolei LI, Zhaoxiao LUO, Tianshun REN. Correlation between cardiometabolic index and metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(10): 2247-2251. doi: 10.3969/j.issn.1001-5256.2022.10.010
[11]	Zhenzhen ZHANG, Yaoyi ZHANG, Kai WANG, Chenguang TIAN. Effect of dapagliflozin on metabolic markers and autonomic function in patients with type 2 diabetes mellitus and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(12): 2849-2853. doi: 10.3969/j.issn.1001-5256.2021.12.023
[12]	Lidan YANG, He HE, Zhenmei AN. Role of intestinal flora in metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2231-2235. doi: 10.3969/j.issn.1001-5256.2021.09.046
[13]	Qianqian XIAO, Mengyu WANG, Jiangao FAN. Brief introduction of APASL clinical practice guidelines on metabolic associated fatty liver disease (Treatment Part)[J]. Journal of Clinical Hepatology, 2021, 37(1): 41-45. doi: 10.3969/j.issn.1001-5256.2021.01.009
[14]	Junzhao YE, Yansong LIN, Bihui ZHONG. Research advances in dietary intervention in the treatment of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(3): 709-713. doi: 10.3969/j.issn.1001-5256.2021.03.042
[15]	Lei MIAO, Liangjie TANG, Jiangao FAN, Minghua ZHENG. Acute-on-chronic liver failure in patients with metabolic associated fatty liver disease: Past, Present, and Future[J]. Journal of Clinical Hepatology, 2021, 37(4): 761-764. doi: 10.3969/j.issn.1001-5256.2021.04.004
[16]	Sutong LIU, Kaiqi SU, Chenlu ZHAO, Lihui ZHANG, Wenxia ZHAO. Research advances in medical treatment of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 947-950. doi: 10.3969/j.issn.1001-5256.2021.04.048
[17]	Jiahui LYU, Xiaofei LI, Lianyi GUO. Association between metabolic associated fatty liver disease and sleep disorders[J]. Journal of Clinical Hepatology, 2021, 37(12): 2854-2860. doi: 10.3969/j.issn.1001-5256.2021.12.024
[18]	LIU YingYing, LIU YuPing, LIU YouRen, SUN Ping. Implementation of aerobic exercise intervention in patients with metabolic associated fatty liver disease:A prospective study[J]. Journal of Clinical Hepatology, 2020, 36(11): 2467-2472. doi: 10.3969/j.issn.1001-5256.2020.11.014
[19]	Xue Rui, Fan JianGao. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1224-1227. doi: 10.3969/j.issn.1001-5256.2020.06.007
[20]	Zhao MengYu, Zou HuaiBin, Chen Yu, Zheng SuJun, Duan ZhongPing. Characteristics and mechanism of virological and liver function changes in pregnant women with chronic hepatitis B virus infection during pregnancy and after delivery[J]. Journal of Clinical Hepatology, 2019, 35(6): 1353-1357. doi: 10.3969/j.issn.1001-5256.2019.06.038

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (350) PDF downloads(49)

Virological features of chronic hepatitis B patients with metabolic associated fatty liver disease： A stratified analysis

DOI: 10.12449/JCH240710

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Virological features of chronic hepatitis B patients with metabolic associated fatty liver disease： A stratified analysis

DOI: 10.12449/JCH240710

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content